Format

Send to

Choose Destination
See comment in PubMed Commons below
Infect Drug Resist. 2010;3:95-101. doi: 10.2147/IDR.S6961. Epub 2010 Aug 30.

Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens.

Author information

  • 1Department of Cardiac Surgery, University Hospital GroƟhadern, Ludwig-Maximilian-University, Munich, Germany;

Abstract

The aim of this review is to summarize the historical background of drug resistance of Gram-positive pathogens as well as to describe in detail the novel lipopeptide antibiotic daptomycin. Pharmacological and pharmacokinetic aspects are reviewed and the current clinical use of daptomycin is presented. Daptomycin seems to be a reliable drug in the treatment of complicated skin and skin structure infections, infective right-sided endocarditis, and bacteremia caused by Gram-positive agents. Its unique mechanism of action and its low resistance profile, together with its rapid bactericidal action make it a favorable alternative to vancomycin in multi-drug resistant cocci. The role of daptomycin in the treatment of prosthetic material infections, osteomyelitis, and urogenital infections needs to be evaluated in randomized clinical trials.

KEYWORDS:

daptomycin; left-sided endocarditis; methicillin-resistant Staphylococcus aureus (MRSA); multi-drug resistance; pneumonia; urinary tract infection

PMID:
21694898
PMCID:
PMC3108743
DOI:
10.2147/IDR.S6961
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center